Patents by Inventor Per Sonne Holm

Per Sonne Holm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF TUMORS BY A COMBINATION OF AN ONCOLYTIC ADENOVIRUS, A CDK4/6 INHIBITOR AND A FURTHER THERAPEUTICALLY ACTIVE AGENT
    Publication number: 20220354911
    Abstract: The present invention is related to a combination of an adenovirus, a CDK4/inhibitor and at least one further agent selected from the group comprising a PARP inhibitor, a bromodomain inhibitor, nutlin or a derivative of nutlin.
    Type: Application
    Filed: September 7, 2020
    Publication date: November 10, 2022
    Inventors: Per Sonne Holm, Roman Nawroth
  • METHOD FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS
    Publication number: 20220339219
    Abstract: The present invention is related to the use of a virus, preferably an adenovirus for reversing resistance in cells.
    Type: Application
    Filed: May 24, 2022
    Publication date: October 27, 2022
    Inventor: Per Sonne Holm
  • Methods for reversing multiple resistance in animal cells
    Patent number: 11369650
    Abstract: The present invention is related to the use of a virus, preferably an adenovirus for reversing resistance in cells.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: June 28, 2022
    Inventor: Per Sonne Holm
  • Use of adenovirus and nucleic acids coding therefor
    Patent number: 11268073
    Abstract: This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: March 8, 2022
    Inventor: Per Sonne Holm
  • TREATMENT OF TUMORS BY A COMBINATION OF AN ONCOLYTIC ADENOVIRUS AND A CDK4/6 INHIBITOR
    Publication number: 20210038661
    Abstract: The present invention is related to a combination of an adenovirus and a CDK4/inhibitor.
    Type: Application
    Filed: March 5, 2019
    Publication date: February 11, 2021
    Inventors: Per Sonne Holm, Roman Nawroth
  • Use of adenovirus and nucleic acids coding therefor
    Patent number: 10731136
    Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or ongogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 4, 2020
    Inventor: Per Sonne Holm
  • USE OF ADENOVIRUS AND NUCLEIC ACIDS CODING THEREFOR
    Publication number: 20200095560
    Abstract: This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.
    Type: Application
    Filed: December 5, 2019
    Publication date: March 26, 2020
    Inventor: Per Sonne Holm
  • Use of adenovirus and nucleic acids coding therefor
    Patent number: 10538744
    Abstract: This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: January 21, 2020
    Inventor: Per Sonne Holm
  • Use of adenoviruses and nucleic acids that code for said viruses
    Patent number: 10300096
    Abstract: The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, whereby the gene is selected from the group comprising E1B55kDa, E4orf6, E4orf3 and E3ADP.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: May 28, 2019
    Inventor: Per Sonne Holm
  • USE OF ADENOVIRUS AND NUCLEIC ACIDS CODING THEREFOR
    Publication number: 20190055522
    Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or ongogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 21, 2019
    Inventor: Per Sonne Holm
  • Use of adenovirus and nucleic acids coding therefor
    Patent number: 10155930
    Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: December 18, 2018
    Inventor: Per Sonne Holm
  • USE OF ADENOVIRUS AND NUCLEIC ACIDS CODING THEREFOR
    Publication number: 20180002674
    Abstract: This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.
    Type: Application
    Filed: March 7, 2017
    Publication date: January 4, 2018
    Inventor: Per Sonne Holm
  • METHODS FOR REVERSING MULTIPLE RESISTANCE IN ANIMAL CELLS
    Publication number: 20170252443
    Abstract: The present invention is related to the use of a virus, preferably an adenovirus for reversing resistance in cells.
    Type: Application
    Filed: March 17, 2017
    Publication date: September 7, 2017
    Inventor: Per Sonne Holm
  • E1-MINUS ADENOVIRUSES AND USE THEREOF
    Publication number: 20170190752
    Abstract: The present invention is related to a virus, preferably an adenovirus, characterised in that the virus comprises: a lacking functional wildtype E1 region, and a transporter for the transport of YB-1 into the nucleus of a cell which is infected with the virus.
    Type: Application
    Filed: March 17, 2017
    Publication date: July 6, 2017
    Inventor: Per Sonne Holm
  • NOVEL USE OF ADENOVIRUSES AND NUCLEIC ACIDS THAT CODE FOR SAID VIRUSES
    Publication number: 20160074447
    Abstract: The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, whereby the gene is selected from the group comprising E1B55kDa, E4orf6, E4orf3 and E3ADP.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 17, 2016
    Inventor: Per Sonne Holm
  • Adenoviruses, nucleic acids coding therefor, and use thereof
    Patent number: 8951772
    Abstract: The present invention is related to an adenovirus expressing a first protein which is selected from the group comprising an E1B protein and an E4 protein, prior to a second protein which is selected from the group comprising an E1A protein.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: February 10, 2015
    Inventor: Per Sonne Holm
  • Use of the adenoviral E2 late promoter
    Patent number: 8921100
    Abstract: The invention relates to a nucleic acid construct comprising an adenoviral E2 late promoter or a fragment thereof and a nucleic acid. The nucleic acid is selected from the group of transgenes, genes and nucleic acids which are respectively different from adenoviral nucleic acid controlled by an E2 late promoter. The invention also relates to the uses of said nucleic acid construct.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: December 30, 2014
    Assignee: Technische Universität München
    Inventor: Per Sonne Holm
  • Adenoviruses, nucleic acids that code for the same and the use of said viruses
    Patent number: 8586354
    Abstract: The present invention is related to an adenovirus expressing a first protein which is selected from the group comprising an E1B protein and an E4 protein, prior to a second protein which is selected from the group comprising an E1A protein.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: November 19, 2013
    Inventor: Per Sonne Holm
  • Adenoviral systems and the uses thereof
    Patent number: 8263067
    Abstract: The invention is related to a nucleic acid comprising an adenoviral nucleic acid, which also comprises a nucleic acid sequence coding for YB-1.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: September 11, 2012
    Inventor: Per Sonne Holm
  • E1-MINUS ADENOVIRUSES AND USE THEREOF
    Publication number: 20120039877
    Abstract: The present invention is related to a virus, preferably an adenovirus, characterised in that the virus comprises: a lacking functional wildtype E1 region, and a transporter for the transport of YB-1 into the nucleus of a cell which is infected with the virus.
    Type: Application
    Filed: July 19, 2011
    Publication date: February 16, 2012
    Inventor: Per Sonne Holm